Vitronectin silencing inhibits hepatocellular carcinoma in vitro and in vivo.

Abstract

AIM:

To explore if inhibition of vitronectin can be used for the treatment of hepatocellular carcinoma.

MATERIALS & METHODS:

RNAi technology was used to silence the expression of VTN in HepG2 and SMMC 7721 cells. Change of growth characteristics in these cells was evaluated.

RESULTS:

VTN silencing does not affect growth characteristics of cancer cells in monolayer cell culture, but could suppress the colonized growth of cells in soft agar. VTN-siRNA suppresses colony formation more than 80% compared with that of control in SMMC7721cells and leads to the inhibition of colony formation of over 70% in HepG2 cells. In addition, VTN silencing decreases the size of tumor xenografts in nude mice, particularly in male mice, with an inhibition rate of 46.6%.

CONCLUSION:

VTN plays a significant role in the malignant growth of tumor. Inhibition of VTN could potentially be applied for the treatment of hepatocellular carcinoma.

• Authors: Wei Zhu, Wenxue Li, Guangyu Yang, Chuanxi Fu, Gaofeng Jiang, Qiansheng Hu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 2 Pg. 251-8 ( 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 25179307 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• RNA, Small Interfering
• Vitronectin

Topics

• Animals
• Carcinoma, Hepatocellular (pathology, therapy)
• Cell Proliferation
• Female
• Gene Knockdown Techniques
• Genetic Therapy
• Hep G2 Cells
• Humans
• Liver Neoplasms (pathology, therapy)
• Male
• Mice, Inbred BALB C
• Mice, Nude
• Neoplasm Transplantation
• RNA Interference
• RNA, Small Interfering (genetics)
• Vitronectin (genetics, metabolism)